...
首页> 外文期刊>Tissue antigens. >Outcome of haematopoietic stem cell transplantation in patients transplanted with matched unrelated donors vs allele-mismatched donors: a single centre study.
【24h】

Outcome of haematopoietic stem cell transplantation in patients transplanted with matched unrelated donors vs allele-mismatched donors: a single centre study.

机译:一项匹配的无关供体与等位基因不匹配的供体移植患者的造血干细胞移植结果:单中心研究。

获取原文
获取原文并翻译 | 示例

摘要

We studied the importance of human leucocyte antigen (HLA)-A, -B and -DRB1 high-resolution matching on the outcome of haematopoietic stem cell transplantation (HSCT) with matched unrelated donors (MUDs) vs single allele-mismatched unrelated donors. Fifty consecutive HSCT patients receiving an HLA-A, -B or -DR allele-level-mismatched unrelated graft (mmUD) were compared with a matched cohort of 100 patients with an HLA-A, -B and -DR-MUD. Rejection occurred in seven patients (14%) in the mmUD group and in four patients (4%) in the MUD group (P = 0.04), but this was mainly an effect of HLA-C mismatch. The cumulative incidence of acute graft vs host disease (GVHD) grades II-IV were 61%, 26% and 33% in the class I mmUD, class II mmUD and MUD groups, respectively. In multivariate analysis, HLA class I mismatch was associated with an increased risk of acute GVHD grades II-IV (2.09, P = 0.007) and transplant-related mortality (TRM) (1.99, P = 0.06). The 5-year overall survival was 81% in patients with a class II allele-mismatched donor compared with 52% (P = 0.025) and 50% (P = 0.017) in patients with a class I mismatch and a MUD. In multivariate analysis, HLA class II allele mismatch was associated with improved survival (3.38, P = 0.019). Relapse-free survival were 53%, 37% and 42% in patients with a class II mmUD, class I mmUD and a MUD, respectively (not significant). An HLA-C or -DQ mismatch had no significant impact on survival, TRM and relapse. In conclusion, compared with MUD, HLA class I allele mmUD had an increased risk of acute GVHD and TRM.
机译:我们研究了人类白细胞抗原(HLA)-A,-B和-DRB1高分辨率匹配对匹配无关供体(MUDs)与单个等位基因不匹配无关供体的造血干细胞移植(HSCT)结果的重要性。将50例接受HLA-A,-B或-DR等​​位基因水平不匹配的不相关移植物(mmUD)的连续HSCT患者与100例HLA-A,-B和-DR-MUD患者的匹配队列进行比较。 mmUD组中有7例患者(14%)发生了排斥反应,MUD组中有4例患者(4%)发生排斥反应(P = 0.04),但这主要是HLA-C错配的影响。 I级mmUD,II级mmUD和MUD组急性移植物抗宿主病(GVHD)II-IV级的累积发生率分别为61%,26%和33%。在多变量分析中,HLA I类错配与急性GVHD II-IV级(2.09,P = 0.007)和移植相关死亡率(TRM)(1.99,P = 0.06)的风险增加相关。 II类等位基因不匹配供体的患者5年总生存率为81%,而I类不匹配和MUD患者的5年总生存率为52%(P = 0.025)和50%(P = 0.017)。在多变量分析中,HLA II类等位基因错配与存活率提高相关(3.38,P = 0.019)。 II级mmUD,I级mmUD和MUD患者的无复发生存率分别为53%,37%和42%(不显着)。 HLA-C或-DQ错配对生存率,TRM和复发没有显着影响。总之,与MUD相比,HLA I类等位基因mmUD的急性GVHD和TRM风险增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号